I-MAB (NASDAQ:IMAB) Stock

I-MAB

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

News

Penny Stocks

Price Target

Markets

Analyst Ratings

Trading Ideas

CSGP

GPOR

IMAB

NVDA

SMAR

TSLA

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday

ABBV

Key Takeaways:


	I-Mab has appointed Raj Kannan as its new CEO, filling its top position 18 months after its last top executive quit
	The new CEO is an industry veteran who engineered sales of his previous two companies after bringing their first drugs to market, hinting that I-Mab could follow a similar path


By Warren Yang

I-Mab Gets New CEO After Long Search. Sale Of The Company Coming Next?

Biotech

Short Ideas

General

On Wednesday, shares of I Mab (NASDAQ: IMAB) experienced volatile short activity. After the activity, the stock price went down -1.86% to $3.16.

The overall sentiment for IMAB has been Bearish.

Short Volatility Alert: I Mab

Earnings

SEED

Origin Agritech FY24 EPS $0.46 Down From $1.17 YoY, Sales $16.18M Up From $13.00M YoY

Motorola Solns (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>) has outperformed the market over the past 20 years by 27.45% on an annualized basis producing an average annual return of 35.86%. Currently, Motorola Solns has a market capitalization of $80.51 billion. 
Buying $1000 In MSI: If an investor had bought $1000 of MSI stock 20 years ago, it would be worth $476,990.10 today based on a price of $481.76 for MSI at the time of writing.
<h3>Motorola Solns's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739227510_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Motorola Solns 20 Years Ago Would Be Worth Today

Rosenblatt analyst Barton Crockett maintains Lions Gate Enter (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LGF#NYSE">LGF</a>) with a Buy and maintains $13 price target.

Lions Gate Entertainment Corporation Class B Non-Voting Shares

LGF/B

Rosenblatt Maintains Buy on Lions Gate Enter, Maintains $13 Price Target

FreeCast's streaming platform will be available to users of the Company's mobile device portfolio. The new integration will give Foxx Development's users immediate access to FreeCast's entertainment hub, consolidating hundreds of streaming services into a single user-friendly interface.

FOXX

Foxx Development Enters Strategic Distribution Agreement With FreeCast

Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) has a history of beating analyst estimates in recent quarters and looks to keep the streak alive with its fourth-quarter financial results before <a href="https://www.benzinga.com/earnings">the market opens Tuesday</a>.
Earnings Estimates: Analysts expect Coca-Cola to report fourth-quarter earnings per share of 52 cents. That&#8217;s up from 49 cents in last year's fourth quarter, according to data<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021025&amp;t=be2bearmibe3na1"> from Benzinga Pro.</a>
The company has beaten analyst estimates for earnings per share in three straight quarters and eight of the last 10 quarters overall. The other two quarters the company didn't beat estimates, the results were in-line with analysts.
Analysts expect Coca-Cola to report fourth-quarter revenue of $10.68 billion, down from $10.85 billion in last year's fourth quarter.
The Atlanta-based company has beaten analyst estimates for revenue in 15 straight quarters, according to Benzinga Pro data.
Read Also: <a href="https://www.benzinga.com/trading-ideas/technicals/25/02/43605038/coca-cola-stock-is-bubbling-higher-can-q4-earnings-keep-the-fizz-going">Coca-Cola Stock Is Bubbling Higher: Can Q4 Earnings Keep The Fizz Going?</a>
What Analysts Are Saying: Piper Sandler analyst Michael Lavery said Coca-Cola has attractive and sustainable growth drivers. In an investor note last month, he highlighted the North America and Latin America regions for seeing strong growth that can be sustainable over the long term.
Lavery initiated coverage on the stock with an Overweight rating and a $74 price target, which was later revised down to $73 later in January.
The analyst said the North America and Latin America regions still have a large percentage of their populations that do not drink commercial beverages, offering an expansion opportunity.
Rising incomes in emerging markets along with population growth could be long-term drivers for "sustainable volume and pricing gains," Lavery said.
Here are other recent<a href="https://www.benzinga.com/quote/KO/analyst-ratings"> analyst ratings on Coca-Cola</a> and their price targets.
<ul>
<li>RBC Capital: Reiterated Outperform rating, raised price target from $68 to $69</li>
<li>Jefferies: Upgraded from Hold to Buy, raised price target from $69 to $75</li>
<li>JPMorgan: Maintained Overweight rating, lowered price target from $75 to $70</li>
<li>Barclays: Maintained Overweight rating, lowered price target from $73 to $66</li>
</ul>
Key Items to Watch: Coca-Cola's earnings report comes after rival PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) recently<a href="https://www.benzinga.com/25/02/43460249/pepsicos-q4-sales-miss-estimates-on-downcast-performance-in-north-america-stock-dives"> reported fourth-quarter financial results. </a>Pepsi shares fell after the report with the company missing analyst estimates.
While Pepsi competes in both the beverage and food markets, the company's North American PepsiCo division is most comparable with the beverage unit of Coca-Cola in North America. This segment saw flat revenue in the quarter for Pepsi.
Coca-Cola's report could include a look at inflation, consumer spending habits and more on how higher prices for several grocery items are impacting spending on beverages.
The beverage giant is a key market indicator as a member of the Dow Jones Industrial Average, although the company's lower share price makes the stock the 28th largest weighting of 30 stocks.
The company's earnings report will also be closely watched by legendary investor Warren Buffett and Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>).
Berkshire Hathaway owns 400 million Coca-Cola shares. The stock is one of the largest holdings of the legendary investor's conglomerate.
Investors and analysts, and maybe Buffett, will be interested to hear if Coca-Cola provides an update on 2025 guidance. <a href="https://www.benzinga.com/news/earnings/24/10/41486650/coca-cola-q3-earnings-eps-beat-pricing-growth-offset-by-volume-decline-sees-10-q4-organic-revenue-g">The company expects</a> adjusted net revenue and earnings per share to have a low single-digit and mid-single-digit currency headwind, respectively.
Price Action: Coca-Cola stock was up 1.1% to $64.55 on Monday versus a 52-week trading range of $57.93 to $73.53. Coca-Cola stock is up 7.5% over the last year.
Shares of rival Pepsi trade at $143.73 versus a 52-week trading range of $141.51 to $183.39. Pepsi stock is down 15.8% over the last year.
Both Coca-Cola and Pepsi shares have underperformed the S&amp;P 500. The SPDR S&amp;P 500 ETF Trust is up 20.7% over the past year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43591420/how-to-earn-500-a-month-from-coca-cola-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Coca-Cola Stock Ahead Of Q4 Earnings</a></li>
</ul>
Image: Shutterstock

Previews

Coca-Cola Q4 Earnings Preview: Can Warren Buffett Favorite Keep Streak Of Revenue Beats Alive?

Rosenblatt analyst Barton Crockett maintains Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) with a Buy and maintains $135 price target.

Rosenblatt Maintains Buy on Walt Disney, Maintains $135 Price Target

Verisk Analytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) has outperformed the market over the past 15 years by 4.86% on an annualized basis producing an average annual return of 16.9%. Currently, Verisk Analytics has a market capitalization of $41.52 billion. 
Buying $1000 In VRSK: If an investor had bought $1000 of VRSK stock 15 years ago, it would be worth $10,407.08 today based on a price of $294.00 for VRSK at the time of writing.
<h3>Verisk Analytics's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739226617_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRSK

Here's How Much $1000 Invested In Verisk Analytics 15 Years Ago Would Be Worth Today

Mild winter weather for the first two months of the quarter contributed to a softer quarter than had been assumed in the company's original forecast.&nbsp;

Guidance

Compass Minerals Cuts 2025 Salt Segment Revenue Outlook From $940M - $1.04B To $900M - $1B

Rosenblatt analyst Hans Mosesmann maintains Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) with a Buy and maintains $85 price target.

LSCC

Rosenblatt Maintains Buy on Lattice Semiconductor, Maintains $85 Price Target

Compass Minerals Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $0.15 by 466.67 percent. The company reported quarterly sales of $307.20 million which beat the analyst consensus estimate of $294.00 million by 4.49 percent. This is a 10.10 percent decrease over sales of $341.70 million the same period last year.

Earnings Beats

Earnings Misses

Compass Minerals Intl Q1 2025 Adj EPS $(0.55) Misses $0.15 Estimate, Sales $307.20M Beat $294.00M Estimate

MARA

MARA Holding Postpones Special Meeting Of Stockholders To February 19, 2025

RCUS

Arcus Biosciences Plans To Present New Data from Casdatifan Via Oral Presentation At 2025 ASCO GU Symposium

&nbsp;S&amp;P 500 constituent Blackstone Inc. is acquiring Retail Opportunity Investments in a deal expected to be completed soon, pending final closing conditions.&nbsp;

GOLF

ROIC

Acushnet Holdings To Replace Retail Opportunity Investments In S&P SmallCap 600 Effective Prior To Opening Of Trading On February 13

EVI Industries Q2 EPS $0.07 Down From $0.09 YoY, Sales $92.7M Up From $91.36M YoY

Goldman Sachs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) has outperformed the market over the past 5 years by 10.02% on an annualized basis producing an average annual return of 22.37%. Currently, Goldman Sachs Gr has a market capitalization of $201.96 billion. 
Buying $100 In GS: If an investor had bought $100 of GS stock 5 years ago, it would be worth $272.93 today based on a price of $650.53 for GS at the time of writing.
<h3>Goldman Sachs Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739225713_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Goldman Sachs Gr Stock In The Last 5 Years

LIXT

LIXTE Biotechnology Submits Request For Withdrawal Of Form S-1 Registration Statement; No Longer Intends To Pursue Public Offering AT This Time

Based on discussions with the Staff, because the Company met the Minimum Bid Price Requirement for 10 consecutive business days as of February 7, 2025, it expects that the Staff would confirm the Company has regained compliance, allowing its common stock to continue trading on Nasdaq without interruption and obviating the need for appealing the delisting determination.

GITS

Global Interactive Technologies Reveals Receipt Of Determination Letter From Nasdaq; Expects Nasdaq Staff Would Confirm Company Has Regained Compliance

Medpace Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) reported fourth-quarter financial results after the market close on Monday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/02/b43608551/medpace-holdings-inc-reports-fourth-quarter-and-full-year-2024-results">of the report</a>.
<ul>
<li>Q4 Revenue: $536.6 million, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $534.78 million</li>
</ul>
<ul>
<li>Q4 EPS: $3.67, versus estimates of $2.96</li>
</ul>
Total revenue was up 7.7% on a year-over-year basis. New business awards totaled $529.7 million in the quarter, down 13.8% year-over-year. The company ended the period with a backlog of approximately $2.9 billion, up 3.2% year-over-year. 
Medpace generated $190.7 million in cash flow from operations during the quarter. The company had cash and cash equivalents of $669.4 million as of Dec. 31.
Medpace said it repurchased $174.2 million of its common stock during the quarter. The company had $134.6 million remaining under its buyback at quarter&#8217;s end. Additionally, Medpace&#8217;s board approved an increase of $600 million to the company&#8217;s buyback program on Feb. 6. 
Check This Out: <a href="https://www.benzinga.com/25/02/43608715/lattice-semiconductor-shares-jump-after-mixed-q4-results-strong-q1-guidance#google_vignette">Lattice Semiconductor Shares Jump After Mixed Q4 Results, Strong Q1 Guidance</a>
Outlook: Medpace expects full-year 2025 revenue to be in the range of $2.11 billion to $2.21 billion. The company sees full-year earnings in the range of $11.93 per share to $12.69 per share. 
Medpace executives will further discuss the quarter on a call with investors and analysts at 9 a.m. ET Tuesday morning.
MEDP Price Action: At publication time Monday, <a href="http://benzinga.com/quote/medp">Medpace shares</a> were down 8.33% at $324.97 in after-hours trading, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Movers

MEDP

Medpace Stock Falls On Q4 Earnings: The Details

Management

Southwest Airlines Names Tom Doxey As Executive Vice President & CFO, Effective March 10

Stock Split

TANH

Tantech Holdings Says Board Approved On January 21 To Effect Share Consolidation Of Common Shares At 1-For-40 Ratio With Effective Date Of February 13

Press Releases

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

I-Mab to Participate at the Truist Securities BioPharma Symposium

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

I-Mab Reports Third Quarter 2024 Results

I-Mab to Participate at the Piper Sandler Healthcare Conference

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member

I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Comments

I-MAB

Loading...

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga